Eli Lilly Raises 2026 Revenue Forecast Following Strong Second-Quarter Growth

Eli Lilly raised its 2026 GAAP revenue guidance to $85 billion to $87 billion after reporting a sharp second-quarter increase in sales, which the company linked to strong demand for its GLP-1 and GIP receptor agonist portfolio.

Second-quarter revenue reached $22.97 billion, up 48% year over year. Net income rose 25% to $7.09 billion, and the company said the quarter’s results came in above consensus analyst forecasts.

Mounjaro and Zepbound drive results across markets

Officials attributed the outperformance primarily to international and Officials attributed the outperformance primarily to international and domestic sales momentum for Mounjaro and Zepbound. The company highlighted these medicines as the central contributors to the quarter’s revenue growth and the improved profit figure. The updated full-year outlook reflects that demand strength, with management pointing to continued traction for its obesity and diabetes franchise. The guidance increase was framed as a response to sustained prescription growth for the portfolio rather than a one-time benefit. EPS range adjusted after acquisition-related R&D charges Alongside the higher revenue outlook, Eli Lilly reduced the top end of its 2026 earnings per share guidance to $36.50. The company kept the low end unchanged at $35.50.

Officials said the revision to the high end of the EPS range reflects $2.8 billion in acquired in-process research and development charges tied to recent acquisitions of Orna Therapeutics and Ajax Therapeutics. The company did not cite a change in underlying demand as the reason for the EPS adjustment.

Analyst response and the operational hinge points to 2027 Following the report, market analysts raised price targets, pointing to operating leverage and margin expansion. Those comments focused on how higher volumes can translate into improved profitability as sales scale.

Looking ahead, the company’s near-term execution priorities remain connected to manufacturing. Future performance, as described by the company and analysts, is tied to the scaling of manufacturing capacity and the continued market penetration of the obesity and diabetes franchise through 2027.

Even with the higher revenue guide, a key uncertainty is how quickly manufacturing expansion can keep pace with demand while supporting continued international and domestic growth for Mounjaro and Zepbound.